Stay updated on Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page has undergone significant updates regarding the study on ovarian cancer, including the introduction of a new drug, ENB003, and changes in the study's revision number from v2.14.4 to v2.15.0. Key personnel involved in the study have also been updated.SummaryDifference52%
- Check19 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 15, 2025, while a date of March 25, 2025, has been removed.SummaryDifference0.4%
- Check27 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check63 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check77 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check84 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy Platform in Platinum-Resistant Ovarian Cancer Clinical Trial page.